| Trial ID: | L0313 |
| Source ID: | NCT00843349
|
| Associated Drug: |
Lanthanum Carbonate
|
| Title: |
Fibroblast Growth Factor-23 (FGF23) Reduction in Predialysis Chronic Kidney Disease (CKD)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00843349/results
|
| Conditions: |
Kidney Disease
|
| Interventions: |
DRUG: Lanthanum Carbonate|OTHER: 900 mg Phosphate Diet|DRUG: LC Placebo|OTHER: Ad Libitum Diet
|
| Outcome Measures: |
Primary: Percentage Changes in Fibroblast Growth Factor-23 (FGF-23) Levels, Nonfasting blood was assessed over a period of 12 weeks. The primary endpoint was percentage change in FGF-23 levels from baseline., Week 0 - 12|Percentage Changes in Parathyroid Hormone (PTH) Levels, Nonfasting blood was assessed over a period of 12 weeks. Endpoint was percentage changes in PTH levels from baseline., Week 0 - 12 |
|
| Sponsor/Collaborators: |
Sponsor: Myles Wolf | Collaborators: National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
43
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION
|
| Start Date: |
2009-07
|
| Completion Date: |
2012-03
|
| Results First Posted: |
2013-06-07
|
| Last Update Posted: |
2013-06-07
|
| Locations: |
University of Miami Hospital, Miami, Florida, 33136, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00843349
|
